ESMO 2019 | Onvansertib with cytarabine or decitabine for R/R AML

Name: Onvansertib with cytarabine or decitabine for R/R AML
Uploaded: 2019-09-27T00:00:00.000Z
Duration: 3 min 35 s
Description: Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, talks about the polo-like kinase 1 (PLK1) inhibitor onvansertib in combination with low-dose cytarabine or decitabine in R/R acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Amer Zeidan • 27 Sep 2019

ESMO 2019

Acute Myeloid Leukemia Leukemia Cytarabine Decitabine Onvansertib

Amer Zeidan, MBBS, MHS, Yale Cancer Center, New Haven, CT, talks about the polo-like kinase 1 (PLK1) inhibitor onvansertib in combination with low-dose cytarabine or decitabine in R/R acute myeloid leukaemia (AML). This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.